SCHEMBL1776776

SCHEMBL1776776

C=CCOC[C@H]1O[C@H](OCC=C)[C@H](OCc2ccccc2)[C@@H](OCc2ccccc2)[C@@H]1O[C@@H]1O[C@H](CO)[C@@H](OCc2ccccc2)[C@H](OCc2ccccc2)[C@H]1OCc1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ SSTR1 P30872 1/20 0.45
▸ SSTR2 P30874 1/20 0.45
▸ SSTR4 P31391 1/20 0.45
▸ SSTR3 P32745 1/20 0.45
▸ SSTR5 P35346 1/20 0.45
▸ PTPN1 P18031 10/20 0.44
▸ CDC25B P30305 8/20 0.44
▸ PTPN2 P17706 5/20 0.43
▸ PTPN11 Q06124 5/20 0.43
▸ SLC6A2 P23975 2/20 0.42
▸ PTPN6 P29350 4/20 0.42
▸ NT5E P21589 1/20 0.41
▸ GJB2 P29033 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1775653 0.96 PTPN1 (0.48) SSTR1SSTR2SSTR4SSTR3SSTR5
SCHEMBL1775656 0.96 PTPN1 (0.48) SSTR1SSTR2SSTR4SSTR3SSTR5
SCHEMBL1776554 0.96 PTPN1 (0.48) SSTR1SSTR2SSTR4SSTR3SSTR5
SCHEMBL1776774 0.94 SLC6A2 (0.47) SSTR1SSTR2SSTR4SSTR3SSTR5
SCHEMBL9167095 0.91 SSTR1 (0.48) SSTR1SSTR2SSTR4SSTR3SSTR5
SCHEMBL13038862 0.91 SSTR1 (0.48) SSTR1SSTR2SSTR4SSTR3SSTR5
SCHEMBL8928604 0.91 SSTR1 (0.48) SSTR1SSTR2SSTR4SSTR3SSTR5
SCHEMBL1775254 0.91 SSTR1 (0.48) SSTR1SSTR2SSTR4SSTR3SSTR5
SCHEMBL1775256 0.91 SSTR1 (0.48) SSTR1SSTR2SSTR4SSTR3SSTR5
SCHEMBL181078 0.90 SSTR1 (0.52) SSTR1SSTR2SSTR4SSTR3SSTR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7943584-B2 Medicinal composition containing diabetes remedy SANKYO COMPANY, LIMITED (JP) 2011-05-17 — — US disclosed
EP-1589023-B1 OLIGOSACCHARIDE DERIVATIVE DAIICHI SANKYO CO LTD (JP) 2010-08-25 — — EP disclosed
US-7632930-B2 Oligosaccharide derivative SANKYO COMPANY LIMITED (JP) 2009-12-15 — — US disclosed
US-20080194495-A1 Oligosaccharide Derivative HONDA TAKESHI 2008-08-14 — — US disclosed
US-7361744-B2 Oligosaccharide derivative SANKYO COMPANY LIMITED (JP) 2008-04-22 — — US disclosed
US-20080039367-A1 Medicinal Composition Containing Diabeted Remedy SANKYO COMPANY, LIMITED (JP) 2008-02-14 — — US disclosed
EP-1792620-A1 MEDICINAL COMPOSITION CONTAINING DIABETES REMEDY Sankyo Company, Limited (JP) 2007-06-06 — — EP disclosed
US-20060025350-A1 Oligosaccharide derivative SANKYO COMPANY, LIMITED (JP) 2006-02-02 — — US disclosed
EP-1589023-A1 OLIGOSACCHARIDE DERIVATIVE Sankyo Company, Limited (JP) 2005-10-26 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080039367-A1 Medicinal Composition Containing Diabeted Remedy DPP4, IAPP, AMY2A SSTR1 879/4885SSTR2 1191/4885SSTR4 457/4885
US-20060025350-A1 Oligosaccharide derivative MAN1B1, FUT6, MAN2A1 SSTR1 373/4885SSTR2 379/4885SSTR4 275/4885
US-20080194495-A1 Oligosaccharide Derivative MAN1B1, FUT6, MAN2A1 SSTR1 373/4885SSTR2 379/4885SSTR4 275/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback